Actively Recruiting
Multi-omics Characterization and Model Construction of Colchicine Anti-inflammatory Therapy Efficacy in ACS Patients
Led by Shanghai Tongji Hospital, Tongji University School of Medicine · Updated on 2025-09-15
380
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this prospective cohort study was to investigate the multi-omics characteristics of the efficacy of colchicine treatment in patients with ACS and to construct a model of efficacy. The main questions the study aims to answer are \- Specific mechanisms of colchicine therapy in patients with ACS; Mechanism-based modelling to identify the population that benefits from colchicine treatment.
CONDITIONS
Official Title
Multi-omics Characterization and Model Construction of Colchicine Anti-inflammatory Therapy Efficacy in ACS Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Between the ages of 18 and 80
- Diagnosis of Acute Coronary Syndrome (STEMI or NSTE-ACS)
- Receiving standardized drug therapy
- Able and willing to provide informed consent
You will not qualify if you...
- Any contraindication to colchicine or known intolerance to colchicine
- Prolonged use of colchicine for other medical conditions
- Women of childbearing age who are pregnant, breastfeeding, or not using effective contraception
- Coronary artery bypass grafting within the last 3 years or planned
- Severe liver impairment with elevated ALT or AST up to three times the upper limit of normal
- Severe kidney impairment with eGFR less than 30 mL/min/1.73m2
- Low platelet count (thrombocytopenia less than 100 x10⁹/L)
- Active diarrhea
- Presence of uncontrollable infectious diseases
- Known immune-related diseases such as lupus, asthma, inflammatory bowel disease, gout, or cancer
- Current use of strong CYP3A4 or P glycoprotein inhibitors without alternatives
- Planning to use systemic anti-inflammatory therapies like NSAIDs, hormones, immunomodulators, or chemotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Tongji Hospital
Shanghai, China, 200000
Actively Recruiting
Research Team
X
Xuebo Liu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here